公司概述
Armata Pharmaceuticals, Inc. operates within the healthcare sector as a clinical-stage biotechnology firm dedicated to developing targeted bacteriophage therapeutics for global antibiotic-resistant infections. The company leverages its proprietary bacteriophage-based technology to create products aimed at treating difficult-to-manage bacterial infections where traditional antibiotics may fail. Currently, the firm maintains a market capitalization of $422.38M and reports a trailing twelve-month revenue of $4.90M, while the specific employee count is not disclosed in available filings. These valuation and revenue figures indicate that the company is a mid-cap entity operating with significant revenue constraints relative to its market cap, a common characteristic for clinical-stage biotechs that have not yet achieved commercial profitability or widespread product launch revenue.
财务健康
The financial statements reveal a substantial operational loss structure, with annual revenue of $4.90M contrasted sharply against a net income loss of -$173,799,000 and an EBITDA of -$29,691,000. The widening gap between the modest revenue of $4.90M and the net income loss of nearly -$174M indicates an extremely fragile cost structure where operating expenses and research costs significantly exceed all revenue generated. Free cash flow stands at -$26,727,500, signaling that the company is burning cash at a rapid rate and lacks the internal liquidity to fund operations without external capital raises. All three margin metrics reflect this financial distress: a gross margin of -220.5%, an operating margin of -775.2%, and a profit margin of 0.0%, which collectively suggest that for every dollar of revenue, the company is losing well over a dollar in costs and expenses. Despite a cash balance of $8.69M, the company carries a substantial debt load of $288.02M, creating a precarious balance sheet where liabilities far outweigh liquid assets. The current ratio of 1.19 suggests that the company possesses just enough current assets to cover current liabilities, indicating tight but technically sufficient short-term liquidity. Furthermore, the return on equity is not available due to the company's loss position, while the return on assets is -23.9%, revealing that management is currently destroying value relative to the asset base rather than generating returns.
估值评估
Valuation metrics for Armata Pharmaceuticals present a complex picture due to the lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -7.34. The negative forward P/E of -7.34 implies that the market is pricing in continued losses or expects earnings to remain negative in the near term, rather than a path to immediate profitability. The price-to-book ratio is listed at -1.92, indicating that the market values the company at a negative multiple relative to its book value, a metric often seen in distressed or highly speculative biotechnology firms. Alternative valuation measures such as a price-to-sales ratio of 86.13 and an EV/EBITDA of -23.63 suggest that the market is valuing the company almost entirely on the potential of its pipeline rather than current financial performance or tangible assets. The stock's trading range over the past year has been volatile, with a 52-week high of $16.34 and a 52-week low of $0.90, illustrating the extreme price sensitivity typical of small-cap clinical-stage biotechs. The beta of 1.40 indicates that the stock's price volatility is 40% higher than the broader market, meaning investors face significantly higher risk exposure to market movements.
Growth & Income
Revenue growth year-over-year stands at -12.1%, while earnings growth is N/A due to the company's consistent losses. The decline in revenue suggests that the company is currently shrinking its top line, which is unusual for a growth-stage biotechnology firm and may point to challenges in product adoption, clinical trial completion, or commercialization efforts. Since the company does not pay a dividend with a yield of N/A and a payout ratio of 0.0%, all available earnings and cash are theoretically available for reinvestment, though currently, the cash is being consumed by operating losses. The company reinvests its limited resources entirely into research and development rather than distributing income to shareholders, a strategy typical of firms prioritizing long-term pipeline advancement over immediate income generation. The overall growth and income profile is characterized by negative revenue momentum and a complete absence of cash return to shareholders, relying solely on external financing to sustain operations.